Precision Medicine Group

Algorics Inc is a Houston-based company that specializes in developing clinical analytics solutions and software for the life sciences industry. Founded in 1980, Algorics focuses on enhancing the efficiency of clinical trials for bio-pharma companies and contract research organizations (CROs) by providing real-time data insights. Its flagship product, the Acuity platform, is a regulatory-compliant, cloud-based solution that transforms data into actionable knowledge, enabling users to evaluate drugs, diseases, and performance effectively. The company also offers Acuity RBM, which facilitates collaboration among teams to identify risks and develop mitigation strategies, and Acuity Insights, which aims to reduce regulatory risks while improving quality and compliance through real-time insights. In August 2015, Algorithm, Inc. rebranded to Algorics Inc, and as of February 2018, it operates as a subsidiary of OmniComm Systems, Inc.

Project Farma is a consulting firm that provides specialized services to healthcare companies within the pharmaceutical and medical device sectors. The firm focuses on biomanufacturing strategy and execution, assisting clients with capital projects, technology transfers, facility construction, and strategy development. Additionally, Project Farma offers expertise in validation processes and ensures compliance with regulatory standards. By addressing the complete supply chain, the firm aims to enhance operational efficiency and support the successful development and production of healthcare products.

ProMedDx is a contract research company that specializes in providing human biologics and supporting clinical services. The company offers a range of services, including annotated biospecimens, patient recruitment, prospective specimen collection, biospecimen procurement, bioprocessing, biostorage, and clinical study monitoring. These services are designed to support the biobanking industry by facilitating global biospecimen management and enhancing direct connections with patients.

Stern Investor Relations, Inc. is an investor relations firm that focuses on serving biotechnology and healthcare companies. Founded in 1998 and headquartered in New York, the firm provides a range of services tailored to the unique needs of entrepreneurial organizations in these sectors. Stern Investor Relations offers expertise in investor and industry research, material assessment, opportunity analysis, strategy development, ESG advising, and executive education. This comprehensive approach enables clients to effectively navigate the complexities of going public and to maintain ongoing investor engagement. As of December 2018, Stern operates as a subsidiary of Precision Medicine Group, Inc., enhancing its capabilities in the dynamic healthcare landscape.

ApoCell, Inc. is a specialty clinical research company that specializes in the identification and analysis of biomarkers in rare circulating cells. The company provides a range of clinical trial support services across therapeutic areas, including oncology, inflammation, diabetes, and chronic kidney disease. Its offerings include sample logistics, project management, biomarker consultation, and companion diagnostics. ApoCell utilizes advanced liquid biopsy technology to detect and isolate circulating tumor cells and other rare cells from whole blood, providing less invasive diagnostic options compared to traditional tumor biopsies. The company also engages in customized biomarker assay development, encompassing proof-of-concept studies, validation of biomarkers, and support for good clinical practice and good laboratory practice studies. ApoCell serves pharmaceutical and biotechnology companies, as well as academic institutions, and has been involved in over 75 clinical studies addressing various cancers. Founded in 2004 and headquartered in Houston, Texas, ApoCell operates additional facilities in Leipzig, Germany, and is a subsidiary of Precision for Medicine, Inc.

Epiontis, founded in 2003 and based in Berlin, Germany, specializes in immune response monitoring and epigenetic assay development. The company utilizes innovative molecular diagnostics technology to provide services that characterize immune status in patients, particularly those undergoing immune-modulating therapies for conditions such as autoimmune diseases and cancer. Epiontis offers a range of established assays for immune cell types, including regulatory T cells and tumor infiltrating lymphocytes, while also developing customized immunomonitoring assays tailored to specific research or clinical needs. Their aim is to support drug companies in immuno-oncology and autoimmune sectors by accelerating the development of effective therapies through precise immune cell monitoring and analysis.

Applied Immunology is a company that offers contract research laboratory services aimed at supporting the development of biological therapeutics and diagnostics. It specializes in cell-based assays and bioanalytical assays, which are essential for the evaluation of biologics. Additionally, the company focuses on clinical immune monitoring of products, providing valuable insights that assist in the therapeutic development process. Through its services, Applied Immunology plays a critical role in advancing the efficacy and safety of new medical treatments.